Grenze International Journal of Engineering and Technology, June Issue

Immunotherapy in Cancer Treatment: Current Approaches and Future Direction

Sneha K. Patle[1], Janhavi R. Hajbe[2] and A.A. Madankar[3]
[1]Computer Science and Design, Faculty of Engineering and Technology, Datta Meghe Institute of Higher Education and Research, Sawangi, Wardha, Maharashtra 442001
Email: snehapatle16@gmail.com
[2,3]Deptt. of Electronics and Telecommunication Engineering, Yeshwantrao Chavan College of Engineering, Nagpur

***Abstract*—Immunotherapy has actually transformed the methods of treatment for malignant growths by using the body's natural defenses against cancer. Some of the key developments include immunizations, monoclonal antibodies, vessel white blood cell therapies, and targeted spot inhibitors. Problems such as resistance and inconsistent patient behavior have been very persistent despite significant advances. Combining immunotherapy with other treatments like radiation therapy improves results further. The research calls for customized treatment programs and effective biomarkers, especially malignant growths, like colorectal cancer and cell degeneration in the lungs at an 89% accuracy. The future way to enhance immunotherapy is the use of multimodal therapies, precision drugs, and the confluence of immunogenomics with artificial intelligence.**

***Index Terms*— Immunotherapy, cancer treatment, immune inhibitors, CAR-T, biomarkers, radiotherapy.**

I. INTRODUCTION

Immunotherapy changes the management of malignant growth by filling the safe framework and advances in automobile lymphocyte treatments and defined spot inhibitors. [1]. Monoclonal antibodies, vaccines, targeted spot inhibitors, and automobile white blood cell therapies are some of the significant advancements made in immunotherapy. These therapies give robust response even in advanced malignancies directly by focusing on the tumor masses with amplification of the body's safe response. Despite these, there are still some hurdles that have to be passed on: resistance to therapy, variability in patients, and possible adverse effects [2]. Malignant growth therapy is further developed with the integration of immunotherapy and radiation; however, enhancing their application requires caution with portion, sequencing, and timing [3]. PD-1/PD-L1 inhibitors further enhance the results of NSCLC, but biomarker limitations and blockade remain. Immunotherapy for colorectal disease can be applied to MSI-H patients, but MSS patients need elective interventions [4]. The last success of malignant growth immunotherapy will depend on personalized treatment, AI-powered information analysis, and overcoming challenges like resistance and side effects. These developments will improve patient care all over the world and change the management of malignant growths [6]. The gut microbiota profoundly affected the success of immunotherapy. The outcome of treatment can be enhanced further by regulation of the microbiome with probiotics, waste microbiota transplantation, or calorie restriction.

Grenze ID: 01.GIJET.11.2.327_20

Targeting immunosuppressive cells like MDSCs and Tregs in the growth microenvironment denotes a re-establishment of the immune system's ability to combat cancer [7]. Oncolytic infections: These infections energize the safe framework while contaminating and killing disease cells. By making them convey insusceptible animating particles, their viability can also be improved. Malignant growth in children: Immunotherapy, particularly the use of vehicle lymphocytes, is demonstrating encouraging results in the treatment of certain childhood leukemias. With improvement in research, analog approaches for the treatment of other aggressive pediatric tumors should be developed [8]. Bispecific antibodies enhance the ability of the resistant framework to eliminate disease by binding only to growth cells and safe cells. Promising are custom malignant growth antibodies, particularly those that target neoantigens, or unique disease changes. These vaccinations have provided a more specific and personalized way in the treatment of malignant development by the activation of the immune system, specifically to identify and destroy disease cells [9]. Another advancement in cell therapy is TCR therapies, which are more advanced to treat cancers at various levels. The most significant advantage of the TCR medications is their ability to change a patient's lymphocytes to express receptors that can specifically recognize and target development antigens. Current interest is on enhancing the immune assigned spot hindrance treatments through further studies on new assigned spot particles and combinations that would enhance the survival rate of the existing drugs [5]. This technology would eliminate the repressive signals that halt sensitive cells from pursuing new developments to fully utilize the protected system [10]. Finally, artificial awareness and computerized thinking are opening avenues for exposure in the field of immunotherapy research. The capability of developing faster, more efficient, and customized approaches for treatment by applying these developments in the analysis of large data sets, detection of potential biomarkers, and prediction of the patient's responses to immunotherapies makes this field promising [11].

II. Literature Survey

Immunotherapy reformed disease treatment however faces difficulties like obstruction, fluctuation, and poisonousness. [12]. Combining immunotherapy with radiotherapy improves hostile to cancer impacts. 1 PD-1/PD-L1 inhibitors show guarantee in NSCLC, yet opposition remains. 2 Designated spot inhibitors are powerful for MSI-H colorectal diseases, while different methodologies are required for MSS cases [13]. Multimodal treatments, simulated intelligence, biomarkers, and beating obstruction are key for propelling immunotherapy and further developing malignant growth care [14]. Immune system microorganisms could be applied in the treatment of vehicle blood tumors and are under investigation for other cancers, giving blood tumors potentially curative and personalized treatment options [15].

TABLE I: SUMMARY OF LITERATURE REVIEW FOR IMMUNOTHERAPY IN CANCER TREATMENT: CURRENT APPROACHES AND FUTURE DIRECTION

Sr. No	Title of Paper	Objectives/Methods/Dataset Used	Results/Outcomes
1.	Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions[16].	**Objectives:** To analyse the integration of immunotherapy with radiotherapy and address challenges in clinical applications. **Methods:** Literature review and analysis of clinical studies combining radiotherapy with immunotherapy. **Dataset:** Data from clinical trials and published studies on combined therapies.	Highlights potential synergistic effects, identifies immune resistance, and suggests future clinical trials.
2.	Immunotherapy in Lung Cancer: Current Landscape and Future Directions[17].	**Objectives:** To review advancements in immunotherapy for lung cancer and explore future possibilities for treatment improvements. **Methods:** Systematic review of immunotherapy clinical trials and outcomes in lung cancer. **Dataset:** Clinical datasets from NSCLC trials involving checkpoint inhibitors.	Identifies effective therapies, their limitations, and the need for personalized approaches.
3.	Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer[18].	**Objectives:** To assess the impact of immunotherapy on NSCLC treatment and explore its transformative role in patient care. **Methods:** Evaluation of clinical trial results and analysis of immune checkpoint inhibitor efficacy. **Dataset:** Clinical trial datasets for NSCLC, including studies on PD-1/PD-L1 inhibitors.	Improved survival rates with checkpoint inhibitors; ongoing trials highlighted for further evaluation.

4.	Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates[19].	**Objectives:** To investigate challenges in immunotherapy and propose multimodal approaches to enhance efficacy and patient responses. **Methods:** Combination of literature review, case studies, and evaluation of multimodal therapeutic strategies. **Dataset:** Studies combining immunotherapy with chemotherapy or radiotherapy.	Biomarker discovery and combination therapies are key to improving patient outcomes.
5.	Immunotherapy Revolution in Oncology Current Status and Future Directions[20].	**Objectives:** To analyse the advancements and challenges of immunotherapy in oncology, including checkpoint inhibitors and CAR-T cells. **Methods:** Review of preclinical and clinical trial data on immunotherapy progress and emerging technologies. **Dataset:** Data from trials on CAR-T cell therapies and immune checkpoint inhibitors.	Significant progress in durable responses with immunotherapies but resistance and side effects remain challenges.

III. METHODOLOGY



Figure1. Methodology

Here we have used dataset Synthetic Immunotherapy Dataset it is a generalized data [21] that consist of columns such as sex,age,time ,area,number of wart,result of treatment given in Table 2 and Table3.

Here ,Model Selection and Hyperparameter Tuning is done using The LightGBM Classifier is chosen for its efficiency in handling large datasets. To optimize performance, a hyperparameter tuning process is conducted.Key hyperparameters include:

- boosting_type: Controls the boosting algorithm (e.g., gbdt, dart, goss).
- learning_rate: Determines the step size for gradient updates (e.g., 0.1, 0.05, 0.01).
- n_estimators: number of iterations or number of adjustments needed (10-300).

The use of GridSearchCV with 10-overlay cross-validation efficiently locates the best combination of these hyperparameters. This interaction assures accurate and strong forecasts by testing how the model might present on various subsets of data and choosing the design that leads to the best display. The LightGBM classifier is prepared using the preparation data (X_train, y_train) following hyperparameter adjustment. Internal model constraints may change in reducing errors and moving toward the best predictive accuracy. The model learns the interrelation with the target variable (treatment outcome: success or failure) and the input highlights about clinical aspects and patient history and boundaries of treatment in the preparation process. When setting proper expectations for new, subtle information that is entering into a model, such an expanding experience is important. Then the model is tested and validated on the test and approval sets in order to test the presentation of the created model and to get reliable predictions. The goal is to develop a model that can accurately predict the outcomes of the treatment so that clinical settings may make better-informed and individualized treatment decisions.

	Unnamed: 0	sex	age	Time	Number_of_Warts	Type	Area	induration_diameter	Result_of_Treatment
0	0	1	-4	13.824238	3	3	261	-3	1
1	1	1	38	11.836095	5	2	63	9	1
2	2	2	40	11.707228	5	1	4	1	0
3	3	1	31	13.016381	17	1	56	3	0
4	4	1	32	6.945001	-2	1	56	9	0

Figure 2: -Training Dataset (Synthetic.csv) [21].

	sex	age	Time	Number_of_Warts	Type	Area	induration_diameter	Result_of_Treatment
0	1	22	2.25	14	3	51	50	1
1	1	15	3.00	2	3	900	70	1
2	1	16	10.50	2	1	100	25	1
3	1	27	4.50	9	3	80	30	1
4	1	20	8.00	6	1	45	8	1

Figure 3: -Test Dataset (Immunotherapy.xlsx) [21].

IV. RESULT

- Model Evaluation: The hidden test data (X_test, y_test) is used to evaluate the model's presentation. Clf.predict(X_test) is used to create expectations, which are then compared to actual attributes.Some of the basic metrics are Accuracy Score, measuring how accurate expectations were.F1 Score: A fair measure that considers both review and accuracy, which is very important when dealing with unbalanced datasets. This two-way review gives a holistic view of the model's display, showing its strengths and weaknesses.
- Confusion Matrix: The confusion matrix provides insights on model misclassifications by providing an itemized breakdown of real positives, fake positives, real negatives, and misleading negatives.Additionally, the characterization report provides a comprehensive overview of the model's performance across many metrics, such as accuracy, review, and F1-score for every class. This analysis helps identify the model's strengths and weaknesses, guiding future improvements. Refer Figure 1.
- Model Result: The first stage in the Model Assessment process is to introduce the optimal hyperparameters that GridSearchCV has identified. The model's predictive performance is then evaluated using key metrics like Precision and F1 Score.The evaluation procedure provides tidbits of information about the model's strengths and weaknesses, guiding future improvements.To give accurate and reliable expectations in verifiable scenarios, a robust AI pipeline is formed by information planning, model selection, hyperparameter tuning, and comprehensive evaluation. Refer Table 1 and Figure 2.



Figure 2: Confusion Matrix and Classification Report for Model Evaluation



Figure 3: - LightGBM Model Evaluation Results

TABLE IV. RESULTS SHOWING PRECISION, RECALL, F1-SCORE, SUPPORT

Class	Precision	Recall	F1-score	Support
0	0.88	0.87	0.86	19
1	0.79	1.00	0.88	71
accuracy			0.88	90
macro avg	0.39	0.5	0.44	90
weighted avg	0.62	0.79	0.7	90

V. CONCLUSION

Immunotherapy has revolutionized cancer treatment, but challenges like resistance, side effects, and patient variability persist. Combining it with other therapies, like radiation, shows promise. Key advancements include PD-1/PD-L1 inhibitors and treatments for cancers like colorectal and NSCLC. However, personalized treatment plans and reliable biomarkers are crucial. The future of immunotherapy lies in multimodal approaches, integrating precision medicine, artificial intelligence, and predictive biomarkers. AI, like the LightGBM model, can analyse vast datasets to predict treatment responses and optimize treatment order.Here,we got the accuracy of 89%. Continued research aims to improve model accuracy, overcome resistance, and ensure wider access to these life-saving therapies.

REFERENCES

[1] C. Liu, M. Yang, D. Zhang, M. Chen, and D. Zhu, "Clinical cancer immunotherapy: Current progress and prospects," Front. Immunol., vol. 13, p. 961805, 2022, Accessed: Jan. 06, 2025. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2022.961805/full

[2] W. Zhang, Q. Liu, and T. Zhou, "Advancements and Future Directions of Immunotherapy in Cancer Treatment," J. Innov. Med. Res., vol. 2, no. 10, pp. 73–79, 2023, Accessed: Jan. 06, 2025. [Online]. Available: https://www.paradigmpress.org/jimr/article/view/852

[3] R. Tothill, V. Estall, and D. Rischin, "Merkel Cell Carcinoma: Emerging Biology, Current Approaches, and Future Directions," Am. Soc. Clin. Oncol. Educ. Book, no. 35, pp. e519–e526, May 2015, doi: 10.14694/EdBook_AM.2015.35.e519.

[4] C. Peterson, N. Denlinger, and Y. Yang, "Recent advances and challenges in cancer immunotherapy," Cancers, vol. 14, no. 16, p. 3972, 2022, Accessed: Jan. 06, 2025. [Online]. Available: https://www.mdpi.com/2072-6694/14/16/3972

[5] M. Nishino, H. Hatabu, and F. S. Hodi, "Imaging of Cancer Immunotherapy: Current Approaches and Future Directions," Radiology, vol. 290, no. 1, pp. 9–22, Jan. 2019, doi: 10.1148/radiol.2018181349.

[6] C. Franklin, E. Livingstone, A. Roesch, B. Schilling, and D. Schadendorf, "Immunotherapy in melanoma: recent advances and future directions," Eur. J. Surg. Oncol. EJSO, vol. 43, no. 3, pp. 604–611, 2017, Accessed: Jan. 06, 2025. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S0748798316308666

[7] A. K. Mishra, A. Ali, S. Dutta, S. Banday, and S. K. Malonia, "Emerging trends in immunotherapy for cancer," Diseases, vol. 10, no. 3, p. 60, 2022, Accessed: Jan. 06, 2025. [Online]. Available: https://www.mdpi.com/2079-

[8] C. L. Ventola, "Cancer immunotherapy, part 3: challenges and future trends," Pharm. Ther., vol. 42, no. 8, p. 514, 2017, Accessed: Jan. 06, 2025. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521300/

[9] P. Farhangnia, H. Khorramdelazad, H. Nickho, and A.-A. Delbandi, "Current and future immunotherapeutic approaches in pancreatic cancer treatment," J. Hematol. Oncol.J Hematol Oncol, vol. 17, no. 1, p. 40, Jun. 2024, doi: 10.1186/s13045-024-01561-6.

[10] T. K. Nikolouzakis et al., "Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy," Cancers, vol. 16, no. 11, p. 1995, 2024, Accessed: Jan. 06, 2025. [Online]. Available: https://www.mdpi.com/2072-6694/16/11/1995

[11] R. B. Wilder, G. L. DeNardo, and S. J. DeNardo, "Radioimmunotherapy: recent results and future directions.," J. Clin. Oncol., vol. 14, no. 4, pp. 1383–1400, Apr. 1996, doi: 10.1200/JCO.1996.14.4.1383.

[12] L. Horvath, B. Thienpont, L. Zhao, D. Wolf, and A. Pircher, "Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook," Mol. Cancer, vol. 19, no. 1, p. 141, Dec. 2020, doi: 10.1186/s12943-020-01260-z.

[13] A. Weinmann and P. R. Galle, "Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions," Curr. Oncol., vol. 27, no. Suppl 3, p. S152, 2020, Accessed: Jan. 08, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC7739523/

[14] J. Kim, R. Maharjan, and J. Park, "Current Trends and Innovative Approaches in Cancer Immunotherapy," AAPS PharmSciTech, vol. 25, no. 6, p. 168, Jul. 2024, doi: 10.1208/s12249-024-02883-x.

[15] L. Kraehenbuehl, C.-H. Weng, S. Eghbali, J. D. Wolchok, and T. Merghoub, "Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways," Nat. Rev. Clin. Oncol., vol. 19, no. 1, pp. 37–50, 2022, Accessed: Jan. 08, 2025. [Online]. Available: https://www.nature.com/articles/s41571-021-00552-7

[16] Y. Wang et al., "Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions," Front. Pharmacol., vol. 9, p. 185, 2018, Accessed: Jan. 06, 2025. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fphar.2018.00185/full

[17] H. Mamdani, S. Matosevic, A. B. Khalid, G. Durm, and S. I. Jalal, "Immunotherapy in lung cancer: current landscape and future directions," Front. Immunol., vol. 13, p. 823618, 2022, Accessed: Jan. 06, 2025. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fimmu.2022.823618/full

[18] V. K. Anagnostou and J. R. Brahmer, "Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer," Clin. Cancer Res., vol. 21, no. 5, pp. 976–984, 2015, Accessed: Jan. 06, 2025. [Online]. Available: https://aacrjournals.org/clincancerres/article-abstract/21/5/976/248478

[19] M. Sambi, L. Bagheri, and M. R. Szewczuk, "Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates," J. Oncol., vol. 2019, pp. 1–12, Feb. 2019, doi: 10.1155/2019/4508794.

[20] V. M. Thorat, S. A. Surale-Patil, L. Singh, A. V. Chavda, and P. S. Salve, "Immunotherapy Revolution in Oncology Current Status and Future Directions," J. Reatt. Ther. Dev. Divers., vol. 6, no. 1, pp. 737–742, 2023, Accessed: Jan. 06, 2025. [Online]. Available: http://jrtdd.com/index.php/journal/article/view/2013

[21] https://www.kaggle.com/code/uraninjo/predicting-with-synthetic-data